Adaptive Biotechnologies (ADPT)
Provides clonoSEQ residual-disease testing and immune-receptor discovery services.
$27.66
vs last close−0.40 (−1.43%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 98.38% | 157.00M shares | |
|---|---|---|---|
| 309 holders · as of Jun 30, 2026 | |||
| Insiders | 1.64% | 2.61M shares | |
| 11 holders · as of Sep 18, 2026 | |||
| Adds to | 100.02% | ||
159.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 100.02%; nothing is left for Other.
13F, as of Jun 30, 2026
309 holders · 157.00M shares · 53 new positions · 163 increased · 88 reduced · 47 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Viking Global Investors LP | 29.99M | 18.79% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 15.14M | 9.49% | +1.84M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.40M | 4.01% | +309.4K | Aug 13, 2026 |
| Wellington Management Group LLP | 5.91M | 3.70% | +2.05M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 5.48M | 3.43% | +984.8K | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 4.63M | 2.90% | +2.66M | Aug 14, 2026 |
| Westfield Capital Management Co LP | 4.27M | 2.67% | −1.17M | Aug 12, 2026 |
| Geode Capital Management, LLC | 3.64M | 2.28% | +5.8K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Viking Global Investors LP | 18.80% | 29.99M | 13G | May 15, 2026 |
| BlackRock, Inc. | 7.90% | 11.99M | 13G | Jan 21, 2026 |
| Nikko Asset Management Co., Ltd. (“NAM”)incl. Sumitomo Mitsui Trust Group, Inc. (“SMTG”) | 5.24% | 7.73M | 13G | Nov 5, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Francis Loofficer: Chief People Officer | Sale · 2 lots | 115,406 | $28.06 | 220,867 |
| Sep 15, 2026 | Susan Bobulskyofficer: Chief Commercial Officer, MRD | Sale | 1,195 | $27.00 | 395,794 |
| Aug 26, 2026 | Katey Einterz Owendirector | Sale | 9,615 | $26.00 | 78,639 |
| Aug 18, 2026 | Robert Hershbergdirector | Sale · 2 lots | 30,664 | $24.40 | 46,683 |
| Aug 18, 2026 | Chad M. Robinsdirector, officer: CEO and Chairman | Sale · 2 lots | 278,676 | $24.48 | 2,180,518 |
| Aug 17, 2026 | Chad M. Robinsdirector, officer: CEO and Chairman | Sale · 2 lots | 321,324 | $25.08 | 2,180,518 |
| Aug 17, 2026 | Peter M. Neupertdirector | Sale · 3 lots | 124,690 | $25.15 | 130,625 |
| Aug 10, 2026 | Susan Bobulskyofficer: Chief Commercial Officer, MRD | Sale | 3,000 | $25.00 | 396,989 |
| Jul 30, 2026 | Susan Bobulskyofficer: Chief Commercial Officer, MRD | Sale | 1,299 | $24.00 | 399,989 |
| Jul 21, 2026 | Harlan S. Robinsofficer: Chief Scientific Officer | Sale · 2 lots | 492,400 | $21.89 | 812,058 |
House and Senate disclosures
Not reported.